VTVT - vTv Therapeutics and Cantex ink licensing agreement for azeliragon development

vTv Therapeutics (VTVT) have entered into a licensing agreement under which Cantex has obtained exclusive worldwide rights to develop and commercialize azeliragon.Azeliragon, also known as TTP488, is an orally active, small molecule, antagonist of the receptor for advanced glycation endproducts ((RAGE)).Under the terms of the agreement, Cantex will be responsible for the development and commercialization of azeliragon and the companies will allocate downstream profits under a tiered arrangement."RAGE is a highly attractive target for the treatment of a wide spectrum of disorders," vTv CEO Steve Holcombe said.vTv Therapeutics shares up marginally during premarket trading.

For further details see:

vTv Therapeutics and Cantex ink licensing agreement for azeliragon development